Novo Shares Jump as Wegovy Pill Sales Blow Past Estimates
Novo Nordisk shares rose sharply on Wednesday, 04 November 2026, after the Danish drugmaker reported third-quarter earnings that beat expectations and raised its full-year outlook, driven by surprisingly strong sales of its oral Wegovy obesity pill.
The results, released early Wednesday, showed that sales of the Wegovy pill — a once-daily oral formulation of semaglutide — blew past analyst estimates, signaling that patients and physicians are embracing the convenience of a pill over weekly injections. The company did not disclose the exact sales figure in the source text, but the magnitude of the beat was enough to prompt an upward revision to guidance.
Why the Pill Format Is a Game-Changer for Obesity Drugs
The obesity drug market has been dominated by injectable GLP-1 therapies, but oral options could dramatically expand the addressable population. Pills are easier to manufacture at scale, simpler to distribute, and remove the needle barrier that deters some patients. Novo’s oral Wegovy is the first major entrant in this space, and its early sales trajectory suggests pent-up demand.
Competitor Eli Lilly ($LLY) also has oral GLP-1 candidates in development, but Novo’s first-mover advantage in the pill format could help it defend market share. The raised outlook implies management now expects the pill to contribute meaningfully to revenue in the current fiscal year, not just future periods.
The Numbers Behind the Guidance Hike
Novo did not specify the exact new guidance range in the source text, but the upward revision is notable given the company had already issued a forecast earlier in the year. The beat on both earnings and revenue suggests that Wegovy pill sales are not cannibalizing injectable sales but rather adding to the franchise.
Investors will watch for the exact revenue contribution from the pill when Novo files its full quarterly report. The stock’s jump on Wednesday, 04 November 2026, indicates that the market views the pill as a durable growth driver rather than a one-off.
Competitive Landscape and Manufacturing Constraints
Novo and Lilly have both faced supply constraints for their injectable obesity drugs. The pill format could alleviate some of that pressure because manufacturing oral solid doses is generally simpler and cheaper than fill-finish for injectables. However, Novo has not disclosed whether it has sufficient manufacturing capacity to meet demand for the pill.
If supply becomes a bottleneck, the raised guidance could prove conservative — or it could be at risk if the company cannot scale production quickly. Investors should monitor any commentary from management on capacity expansion during the earnings call.
What to Watch: Q4 Prescription Trends and 2027 Guidance
The next catalyst will be the company’s fourth-quarter prescription data for the Wegovy pill, expected in early 2027. A sustained increase in weekly prescription volumes would confirm that the initial beat was driven by real demand rather than channel stocking. Additionally, Novo’s initial 2027 guidance, likely to be issued with its Q4 results, will show whether management expects the pill to become a primary growth driver or a niche add-on.
Any indication that supply is constraining sales, or that competitors are gaining traction with their own oral candidates, would challenge the bull case. For now, the raised outlook and the stock’s positive reaction suggest that Novo has bought itself time to prove the pill’s long-term potential.
Sources: cnbc.com